SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

28.68 2.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

28.54

Max

28.76

Põhinäitajad
By Trading Economics
Sissetulek	-13M -19M
Müük	-24M 3M
Kasumimarginaal	-618.236
Töötajad	103
EBITDA	-14M -13M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+18.47% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	20. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-50M 1.3B
Eelmine avamishind	26.47
Eelmine sulgemishind	28.68

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. apr 2026, 23:48 UTC

Uudisväärsed sündmused

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19. apr 2026, 23:36 UTC

Uudisväärsed sündmused

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19. apr 2026, 22:47 UTC

Uudisväärsed sündmused

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

20. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

20. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19. apr 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19. apr 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19. apr 2026, 23:38 UTC

Uudisväärsed sündmused

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19. apr 2026, 23:12 UTC

Uudisväärsed sündmused

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19. apr 2026, 23:10 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19. apr 2026, 23:09 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19. apr 2026, 23:08 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18. apr 2026, 01:00 UTC

Uudisväärsed sündmused

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17. apr 2026, 22:58 UTC

Tulu

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17. apr 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17. apr 2026, 20:52 UTC

Tulu

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17. apr 2026, 20:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

18.47% tõus

12 kuu keskmine prognoos

Keskmine 34 EUR 18.47%

Kõrge 34 EUR

Madal 34 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.